Reference Detail

Ref Type

PMID

Authors

Noah M. Hahn, Trinity J. Bivalacqua, Ashley Ross, George J. Netto, Jong Chul Park, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard Foster, Thomas A. Gardner, Liang Cheng, David R Jones, Kyle McElyea, George Sandusky, Ziyue Liu et al

Title

Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.

Journal	Vol	Issue	Date	Pages	Journal Short Title
J Clin Oncol

URL

http://meetinglibrary.asco.org/content/167294-176

Abstract Text

J Clin Oncol 34, 2016 (suppl; abstr 4526)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...
FGFR3 mut FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...